Post-earnings recap
Reported
Wed, May 8, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
13%
Vaxcyte's earnings report showed a larger-than-expected loss per share, which was a positive surprise compared to expectations. However, the lack of revenue figures and guidance may have contributed to the stock's decline of 1.08%. Investors are likely concerned about the company's future performance without clear direction from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.85 | N/A | +23.42% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to long-term goals despite short-term setbacks.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on advancing its pipeline and operational efficiency.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—